在治疗糖尿病时，我们应该联合使用GLP-1受体激动剂和SGLT2抑制剂吗？ - Suppr

Suppr

超能文献

Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?

作者信息

Packer Milton

机构信息

Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Tex.

出版信息

Am J Med. 2018 May;131(5):461-463. doi: 10.1016/j.amjmed.2017.11.052. Epub 2018 Jan 5.

DOI:10.1016/j.amjmed.2017.11.052

PMID:29309741

Abstract

摘要

相似文献

Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?在治疗糖尿病时，我们应该联合使用GLP-1受体激动剂和SGLT2抑制剂吗？

Am J Med. 2018 May;131(5):461-463. doi: 10.1016/j.amjmed.2017.11.052. Epub 2018 Jan 5.

Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.基于人群队列研究的 2 型糖尿病患者胰高血糖素样肽-1 受体激动剂与钠-葡萄糖共转运蛋白 2 抑制剂的心血管比较效果。

Diabetes Obes Metab. 2022 Aug;24(8):1623-1637. doi: 10.1111/dom.14741. Epub 2022 May 25.

Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的心血管疗效和安全性：系统评价和网络荟萃分析。

Diabet Med. 2019 Apr;36(4):444-452. doi: 10.1111/dme.13898. Epub 2019 Jan 30.

The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的心血管和肾脏比较效果：斯堪的纳维亚队列研究。

Diabetes Obes Metab. 2022 Mar;24(3):473-485. doi: 10.1111/dom.14598. Epub 2021 Nov 24.

How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.SGLT2（钠-葡萄糖共转运蛋白 2）抑制剂和 GLP-1（胰高血糖素样肽-1）受体激动剂如何降低心血管结局？：已完成和正在进行的机制试验。

Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30.

Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的心血管结局试验的评价。

Curr Opin Cardiol. 2019 Nov;34(6):687-692. doi: 10.1097/HCO.0000000000000673.

Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂对2型糖尿病患者的心血管益处。

Med Lett Drugs Ther. 2019 Feb 25;61(1566):26-28.

Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.糖尿病合并心血管疾病患者中 SGLT2-i 与 GLP1-RA 的合理选择策略。

Curr Cardiol Rep. 2019 Jul 27;21(9):100. doi: 10.1007/s11886-019-1197-6.

[Novel antidiabetic drugs and cardiovascular complications].[新型抗糖尿病药物与心血管并发症]

Ugeskr Laeger. 2018 Feb 5;180(6).

Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.SGLT2 抑制剂和 GLP-1 受体激动剂的肾脏获益：支持 2 型糖尿病医学管理模式转变的证据。

Int J Mol Sci. 2019 Nov 20;20(23):5831. doi: 10.3390/ijms20235831.

引用本文的文献

The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications.糖尿病性射血分数保留的心力衰竭中新型抗糖尿病药物的概况：相关机制及临床意义

Cardiovasc Diabetol. 2025 Apr 28;24(1):186. doi: 10.1186/s12933-025-02750-4.

Switching to Versus Addition of Incretin-Based Drugs Among Patients With Type 2 Diabetes Taking Sodium-Glucose Cotransporter-2 Inhibitors.在服用钠-葡萄糖共转运蛋白 2 抑制剂的 2 型糖尿病患者中，改用与添加基于肠促胰岛素的药物。

J Am Heart Assoc. 2022 Apr 5;11(7):e023489. doi: 10.1161/JAHA.121.023489. Epub 2022 Mar 24.

Calcium Ion Channels: Roles in Infection and Sepsis Mechanisms of Calcium Channel Blocker Benefits in Immunocompromised Patients at Risk for Infection.钙离子通道：在感染和感染风险免疫功能低下患者中钙通道阻滞剂获益的败血症机制中的作用。

Int J Mol Sci. 2018 Aug 21;19(9):2465. doi: 10.3390/ijms19092465.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验